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We investigated the effects of signaling through CD28 family molecules on human immunodeficiency virus type 1 (HIV-1) replication in
vitro. A monoclonal antibody (mAb) specific for inducible costimulator (ICOS) suppressed both X4 and R5 HIV-1 replication in CD4+
peripheral blood mononuclear cells (PBMC). This suppression was not attributable to reduced cell growth or viability. CD28 mAb showed
variable effects and also suppressed HIV-1 replication when immobilized. Replication of pseudotype viruses with HIV-1-but not with
vesicular stomatitis virus G-envelope was efficiently suppressed in CD4+ PBMC treated with ICOS or CD28 mAbs. However, CD4,
CXCR4, and CCR5 expression on the surface was not down-regulated. Moreover, HIV-1 replication in CD4+ PBMC was suppressed by a
soluble form of human B7-H2, a ligand of ICOS, but was enhanced by soluble B7-1, a ligand for CD28. These findings suggest that natural
or artificial ligands for ICOS potentially suppress HIV-1 replication mainly at the entry stages.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV-1 suppression; Immune regulation; Costimulatory molecule; ICOS; CD28; T cell activationIntroduction
HIV-1 proliferates extensively and creates viremia in the
acute phase of HIV-1 infection. Following the acute phase,
the peripheral HIV-1 load declines to low levels that are
continued during the asymptomatic phase of several years
(Ho et al., 1989). Even during the asymptomatic period,
viral replication is maintained at a low level (Pantaleo et al.,
1993; Piatak et al., 1993). HIV-1 production in vivo is
performed by both continuous de novo infections to unin-
fected short-lived cells, and viral persistence in long-life
cells (Ho et al., 1995; Perelson et al., 1996; Wei et al.,
1995). Individuals who receive long-term highly active
antiretroviral therapy retain replication-competent HIV-1
predominantly in the memory T cell fractions, suggesting
that these cells may be the main reservoir of persistently
infecting HIV-1 (Finzi et al., 1997; Wong et al., 1997).
The mechanisms regulating HIV-1 replication in vivo are
not fully understood. HIV-1-specific cytotoxic T cells (CTL)0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.037
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E-mail address: kann.impt@tmd.ac.jp (M. Kannagi).are thought to kill HIV-1-infected cells, although Nef-medi-
ated down-regulation of MHC-I may limit CTL function
(Walker et al., 1987). CD8+ cell-mediated unidentified
soluble and cellular molecules may also contribute to the
suppression of viral replication (Kannagi et al., 1990; Walker
et al., 1986). Neutralizing antibodies might have some effect
on limiting the spread of HIV-1. Besides these host defense
mechanisms, the status of T cell activation may also affect
HIV-1 replication by altering the expression of HIV-1
receptors and cytokines, as well as the status of intracellular
molecules responsible for nuclear transport or transcription.
T cell activation is regulated by signals through a T cell
receptor/CD3 complex and various costimulatory molecules
that interact with their ligands on antigen-presenting cells
(APC) (Lenschow et al., 1996). The first well-characterized
costimulatory molecule was CD28 (Hara et al., 1985),
which mediates positive signals in T cells following inter-
actions with B7-1/CD80 or B7-2/CD86 (Linsley et al.,
1990). Inhibition of CD28 receptors prevented CD3-medi-
ated HIV-1 replication, indicating that CD28 signals are
crucial in HIV-1 replication (Diegel et al., 1993). In contrast,
CD28 may also transmit signals inhibiting HIV-1 replication
when ligated (Levine et al., 1996).
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have been identified including cytotoxic T lymphocyte
antigen 4 (CTLA-4) (Brunet et al., 1987), inducible cos-
timulator (ICOS)/activation-inducible lymphocyte immuno-
mediatory molecule (AILIM)/H4 (Buonfiglio et al., 2000;
Hutloff et al., 1999; Tamatani et al., 2000), and programmed
death gene 1 (PD-1) (Nishimura and Honjo, 2001). CTLA-4
is an inducible molecule homologous to CD28 and also
binds B7-1/CD80 and B7-2/CD86, but transmits negative
signals to T cells (Azuma et al., 1993; Krummel and Allison,
1995; Walunas et al., 1994). ICOS transmits positive signals
following interactions with the ligand B7-H2/B7 homolo-
gous protein (B7h)/B7-related protein 1 (B7RP-1) (Swallow
et al., 1999; Yoshinaga et al., 1999). Stimulation of CD28
results in activation of IL-2, while stimulation of ICOS
induces the production of other cytokines such as IL-4, IL-
5, IL-10, IL-13, IFN-g, TNF-a, and GM-CSF (Beier et al.,
2000; Coyle et al., 2000; Hutloff et al., 1999). PD-1 binds
PD-L1 (B7-H1) and PD-L2 (B7-DC) (Dong et al., 1999;
Freeman et al., 2000; Latchman et al., 2001; Tseng et al.,
2001), and inhibits TCR-mediated proliferation of T cells
and cytokine production. CD28 is constitutively expressed
by Tcells, while other molecules are induced upon activation
(Sharpe and Freeman, 2002).
B7 family molecules are expressed on monocytes,
dendritic cells, and B cells, and sometimes on T cells,
epithelial cells, and endothelial cells (Frauwirth and
Thompson, 2002; Sharpe and Freeman, 2002). Although
B7-1/B7-2 are mainly expressed on lymphoid organs,
B7h, PD-L1, and PD-L2 are also found on nonlymphoid
organs such as the heart, lung, and kidney (Latchman et
al., 2001; Lenschow et al., 1996; Sharpe and Freeman,
2002; Swallow et al., 1999). Thus, interactions between
molecules from the CD28-B7 family may play an impor-
tant role not only in priming T cells, but also in regulating
activated T cells in both lymphoid and nonlymphoid
organs in vivo.Table 1
Effects of mAbs to various CD28 family molecules on HIV-1 replication
Concentration HIV-1 p24 production (pg/ml) in CD4+ PBMC
of mAbs (Ag/ml)
Medium TN228 anti-CD28 MIH8
Exp. 1 0 130.1 F 6.1
10 147.1 F 32.0 158.0
Exp. 2 0 152.8 F 9.7
1 123.5 F 11.2 119.0
2.5 75.9 F 17.5* 149.6
Exp. 3 0 77.2 F 13.8
10 133.0 F 8.6* 70.2
Exp. 4 0 168.8 F 20.6
0.5 183.7 F 14.0 138.4
5 199.2 F 59.0 149.7
PHA-stimulated CD4+ PBMC cells were infected with the X4 HIV-1 strain NL
indicated concentration in 96-well round-bottomed plates. HIV-1 p24 in the supern
experiments using PBMC from different donors are shown. The values indicate t
*P < 0.05.In the present study, we investigate effects of signals
through CD28 family molecules on HIV-1 replication, and
showed that ICOS monoclonal antibody (mAb) mediate
suppression of HIV-1 replication in PHA-stimulated CD4+
T cells in vitro mainly at the early stages of HIV-1 replica-
tion. Furthermore, a soluble form of B7-H2 (B7h) also
mediated signals suppressing HIV-1 replication, suggesting
that natural or artificial ligands for ICOS might be applicable
as a biological strategy to control HIV-1 infection.Results
The effects of mouse monoclonal antibodies (mAbs) for the
CD28 family molecules on HIV-1 replication
To examine the effect of activation signals through the
CD28 family molecules on HIV-1 replication, phytohemag-
glutinin (PHA)-stimulated CD4+ peripheral blood mononu-
clear cells (PBMC) were infected by the X4 strain HIV-1
NL4-3, and cultured in the presence of mAbs for various
CD28 family molecules at concentrations ranging from 0.5
to 10 Ag/ml. HIV-1 replication was monitored by measuring
the levels of HIV-1 p24 in the culture supernatant after 4
days of culture. The results of four experiments using
PBMC isolated from different donors are summarized in
Table 1. Although there was individual variability, SA12, a
mAb to ICOS, significantly suppressed HIV-1 replication.
The effects of the anti-CD28 mAb TN228 varied widely,
enhancing viral replication in some samples, while sup-
pressing it in others. MAbs to CTLA-4 and PD-1 did not
markedly affect HIV-1 replication. Flow cytometric analysis
indicated that PHA-stimulated CD4+ PBMC expressed
significant levels of CD28 and ICOS, but low or undetect-
able levels of PD-1 and CTLA-4 (Fig. 1). We therefore
investigated the effects of ICOS and CD28 signals on HIV-1
replication thereafter.culture in the presence of
anti-CTLA-4 SA12 anti-ICOS MIH4 anti-PD-1 Mouse IgG1
F 27.0 100.0 F 12.1 147.3 F 79.3 135.0 F 16.1
F 12.9* 129.1 F 9.6 134.8 F 20.4 136.0 F 9.6
F 13.7 58.3 F 5.5* 136.4 F 6.2 140.5 F 8.9
F 20.0 39.6 F 7.4* 79.4 F 8.3 82.0 F 11.0
F 14.5 78.5 F 4.4* 146.2 F 14.9 151.5 F 38.2
F 10.5 49.9 F 17.3* 155.1 F 72.3 141.2 F 34.6
4-3 for 2 h and cultured either without or with the indicated mAbs at the
atant was measured by ELISA after 4 days. The results of four independent
he mean F SD from triplicate determinations.
Fig. 1. Cell surface expression of CD28 family molecules on PHA-stimulated CD4+ PBMC. PHA-stimulated CD4+ PBMC cultured in the presence of IL-2 for
6 days were stained with mAbs to CD28, CTLA-4, ICOS, or PD-1 (open histogram), and subsequently stained with FITC-labeled second antibody. Closed
histogram indicates cells stained with second antibody alone.
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ICOS and CD28 mAbs
It has previously been shown that immobilized CD28
mAbs suppress HIV-1 replication in PBMC (Levine et al.,
1996). We then assessed the effects of immobilized ICOS
and CD28 mAbs on X4 and R5 HIV-1 replication. As
shown in Fig. 2, immobilized CD28 and ICOS mAbs
significantly inhibited replication of both X4 HIV-1 NL4-
3 and R5 HIV-1 JR-CSF in CD4+ PBMC. The inhibitory
effect of immobilized ICOS and CD28 mAbs on HIV-1
replication was observed in repetitive experiments. Thus,
ligation of ICOS or CD28 mediated efficient inhibitory
signals in HIV-1 replication in CD4+ T cells regardless of
X4 or R5 HIV-1 strains.
Immobilized ICOS and CD28 mAbs do not suppress cell
proliferation or viability
We next examined whether ICOS- or CD28-mediated
inhibition of viral replication is associated with reduced
proliferation or viability of CD4+ T cells. Fig. 3A shows
HIV-1 replication in PHA-stimulated CD4+ T cells cultured
in either the presence of immobilized ICOS or CD28 mAbs
at concentrations ranging from 0.0125 to 5 Ag/ml for 4 days.
HIV-1 replication was dose-dependently suppressed by
immobilized ICOS or CD28 mAbs, except at the highest
concentration of CD28 mAb, which showed some irregu-
larity. Simultaneously prepared uninfected CD4+ T cells
from the same donor underwent a [3H]thymidine uptakeassay after 4 days of culture in the presence of similar
concentrations of immobilized mAbs. As shown in Fig. 3B,
in contrast to HIV-1 replication, proliferation of CD4+ T
cells was positively correlated with the presence of either
immobilized ICOS or CD28 mAbs in a dose-dependent
manner. As a control, immobilized mouse IgG1 did not
affect either HIV-1 replication or cell proliferation. To assess
whether cell death occurred, we daily monitored the levels
of lactate dehydrogenase (LDH) released into the superna-
tant from CD4+ T cells cultured with immobilized mAbs.
As shown in Fig. 3C, the amount of LDH did not differ
among these CD4+ T cell cultures during 3 days of culture.
These results indicated that the inhibition of HIV-1 replica-
tion by immobilized ICOS or CD28 mAbs was not due to
inhibition of cell proliferation or viability.
ICOS and CD28 mediate inhibition of the early stages of a
HIV-1 replication cycle
To determine at which steps of the life cycle of HIV-1 the
antiviral effect of ICOS or CD28 mAbs occurred, we
monitored HIV-1 cDNA synthesis after infection. PHA-
stimulated CD4+ T cells infected with HIV-1 NL4-3 for
2 h were cultured with immobilized ICOS or CD28 mAbs,
and 106 cells in each well were harvested for DNA analysis
2, 24, and 48 h after infection (Fig. 4). The reverse tran-
scripts were amplified by PCR using specific primer pairs
for HIV-1 LTR R and gag regions (R/gag)(Masuda et al.,
1995; Zack et al., 1990). Twenty-four hours after infection,
the amount of viral cDNA (R/gag) was considerably less in
Fig. 2. Immobilized mAbs for ICOS (SA12) and CD28 (TN228) inhibited
HIV-1 replication. CD4+ PBMC cultured for 4–6 days after PHA
stimulation were infected with X4 HIV-1 NL4-3 (A) or R5 HIV-1 JR
CSF (B) for 2 h, and cultured in medium alone or in the plates precoated
with 5 Ag/ml antibodies indicated. After 4 days, HIV-1 p24 levels in the
supernatant were measured by ELISA. The results indicate the mean F SD
from triplicate determinations. Similar results were obtained in an
independent experiment. *P < 0.05.
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cells not treated with mAbs. Although to a lesser degree
than ICOS mAb, CD28 mAb also inhibited cDNA synthesis
of HIV-1. Similar inhibition of viral cDNA synthesis by
these mAbs was also observed at 14 h following HIV-1
infection in an independent experiment (data not shown).
These results suggest that immobilized ICOS and CD28Fig. 3. Stimulation of ICOS or CD28 suppressed HIV-1 replication but not
the proliferation or viability of CD4+ T cells. (A) PHA-stimulated purified
CD4+ T cells infected with HIV-1 NL4-3 were cultured on plates precoated
with antibodies at the indicated concentration of 5 Ag/ml ( ), 0.25 Ag/ml
( ), and 0.0125 Ag/ml ( ), or in the medium alone ( ) for 4 days, and
HIV-1 P24 levels in the supernatant was measured by ELISA. (B)
Uninfected PHA-stimulated purified CD4+ T cells from the same
donor as A were simultaneously cultured in plates similarly precoated
with antibodies for 4 days, and the incorporation of [3H]thymidine
(TdR) into the cells during the last 16 h was measured as described in
Materials and methods. The results indicate the mean F SD from
triplicate determinations. (C) Cell death of PHA-stimulated purified
CD4+ T cells incubated on plates precoated with antibodies at the
indicated concentrations was determined daily from the level of LDH
in the supernatant over 3 days. The results are shown for 24 h after the
initiation of culture. Similar results were obtained in the second and
third days.mAbs prevent HIV-1 infection during the steps before or at
reverse transcription in the HIV-1 life cycle.
The effects of immobilized ICOS and CD28 mAbs on
pseudotype HIV-1 expression
We next investigated whether ICOS or CD28 mAbs
could suppress the entry steps of HIV-1 replication by using
pseudotype HIV-1 (Masuda et al., 1995; Planelles et al.,
1995) consisting of an envelope-defective HIV-1 expressing
Fig. 4. Analysis of HIV-1 DNA synthesis in NL4-3-infected CD4+ PBMC treated with immobilized ICOS mAb. CD4+ PBMC cultured for 4 days after PHA
stimulation were infected with DNase-treated HIV-1 NL4-3 for 2 h and cultured in 12-well flat-bottomed plates (106 cells/well) precoated with ICOS or CD28
mAbs (5 Ag/ml) or medium alone. Total DNAwas extracted from the cells harvested at the indicated periods after infection and underwent PCR analysis with
the primer pairs for HIV-1 R/gag region. For HIV-1 DNA standards, 250–5000 copies of linearized HIV-1 JR-CSF DNAwere amplified in parallel. Amplified
products were resolved on a 2% agarose gel and visualized by Syber-Green staining (FMC Bioproduct). HIV-1 treated at 65 jC for 30 min before inoculation
was used as a heat-inactivated control (HI).
Fig. 5. Effects of ICOS or CD28 stimulation on pseudotype HIV-1 gene
expression. CD4+ PBMC cultured for 4 days after PHA stimulation were
incubated overnight in plates coated with immobilized ICOS or CD28
mAbs or control mouse IgG (1 Ag/ml) (106/well in 24-well plates), then
infected with luciferase-expressing pseudotype HIV-1 possessing a VSV-G
envelope (A) or a HIV-1 LAI envelope (B) for 2 h. The cells were further
cultured for 48 h on plates coated with the same antibodies as above, and
luciferase activity was measured. The results show the mean F SD from
duplicate determinations. *P < 0.05.
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or VSV-G envelope (Yee et al., 1994). The pseudotype
viruses with HIV-1 envelope enter into cells by envelope-
mediated membrane fusion, whereas the pseudotype viruses
with VSV-G envelope use endocytotic mechanisms. Fig. 5
shows luciferase activities of PHA-stimulated CD4+ PBMC
that were infected with pseudotype HIV-1 and cultured in
the presence of immobilized ICOS or CD28 mAbs. Lucif-
erase expression in the CD4+ PBMC infected with VSV-G
envelope pseudotype virus was increased by CD28 mAbs
and unchanged by ICOS mAbs (Fig. 5A). By contrast,
expression of HIV-1 envelope pseudotype virus was signif-
icantly inhibited by both ICOS and CD28 mAbs (Fig. 5B).
These results indicate that immobilized ICOS and CD28
mAbs mainly affected the entry stages of HIV-1 replication.
ICOS or CD28 stimulation did not reduce HIV-1 receptor
expression on CD4+ T cells
We next assessed whether pretreatment with immobilized
ICOS or CD28 mAbs reduces the expression of HIV-1-
specific receptors on CD4+ T cells. Following 24 h of
preincubation with immobilized ICOS or CD28 mAbs, the
expression of CD4, CXCR4, and CCR5 on PHA-stimulated
CD4+ cells was analyzed by flow cytometry. The purity of
the CD4+ T cells was approximately 93%. The results are
shown in Fig. 6. The expression of CCR5 was significantly
upregulated in cultures pretreated with CD28 or ICOS
mAbs. In these cultures, increased CCR5 expression per-
sisted during the first 4 days after stimulation at least. In
contrast, the levels of CD4 and CXCR4 expression were not
altered by these mAbs. Thus, ICOS- or CD28-mediated
suppression of both X4 and R5 HIV-1 replication could not
be attributed to a reduction in HIV-1-specific receptor
expression on the cell surface.
Fig. 6. Effects of ICOS or CD28 stimulation on HIV-1 receptor expression by CD4+ T cells. PHA-stimulated CD4+ PBMC were treated either with
immobilized mAbs to ICOS (A) or CD28 (B) or control mouse IgG1 (C) (5 Ag/ml) in 24-well flat-bottomed plates, and the expression of CXCR4 and CCR5
receptors was examined by FACS (open histogram) after 24 h of culture. Closed histogram indicates control cells stained with the second antibody alone.
Similar results were obtained in an independent experiment cultured for 3 days.
Table 2
Effect of ICOS and CD28 stimulation on cytokine production (pg/ml) from
PHA-stimulated CD4+ PBMC
Cytokines Early stimulation with Late stimulation with
Mouse
IgG1
SA12 TN228 Mouse
IgG1
SA12 TN228
IL-4 N.D. 4.4 2.3 N.D. N.D. 1.3
IL-5 621.3 1785.1 1514.9 679.6 773.6 1053.4
IL-10 171.6 274.7 246.8 8.9 11.2 13
TNF-a 1599.2 1075.7 942.4 1.8 2.4 2.1
IFN-g 13814.5 2913.4 3858.3 338.5 356.6 419
MIP-1a 1512.7 1629.9 1554.5 379.1 356.7 394
RANTES 3524.4 3565.9 3177.8 426.7 400 429.6
SDF-1a N.D. N.D. N.D. N.D. N.D. N.D.
CD4+ PBMC were placed into plates that were precoated with mouse IgG1,
or SA12 (anti-ICOS) or TN228 (anti-CD28) mAbs at a concentration of
5 Ag/ml, immediately (early stimulation) or 4 days (late stimulation) after
30 min of PHA stimulation, and cultured in the RPMI medium containing
IL-2. Cytokines and chemokines in the supernatants were measured by
using either Cytometric Bead Array Kit (IL-4, IL-5, IL-10, TNF-a) or
ELISA (IFN-g, MIP-1a, RANTES, SDF-1a) 3 days after mAb
stimulations.
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We next examined whether ICOS and CD28 mAbs
altered the production of cytokines and chemokines that
might affect HIV-1 replication. In most of the experiments
above, we added ICOS or CD28 stimulation to CD4+
PBMC that had been cultured for several days after PHA
stimulation. In this condition, the cells stimulated with PHA
alone produced detectable levels of IL-5, IFN-g, MIP-1a,
and RANTES, and very low levels of IL-10 (Table 2).
Among them, IL-5 production was further enhanced by
CD28-stimulation, but other cytokines were not significant-
ly altered by ICOS or CD28 mAbs.
We also examined cytokine production by CD4+ PBMC
stimulated with ICOS or CD28 mAbs immediately after
PHA stimulation. In this condition, the cells with PHA
stimulation alone produced significant levels of IL-5, IL-10,
TNFa, IFNg, RANTES, and MIP-1a. Stimulation of ICOS
and CD28 enhanced IL-5 and IL-10, but reduced TNFa and
IFNg production. RANTES and MIP-1a were not signifi-
cantly affected by ICOS and CD28 mAbs. SDF-1 was not
detectable in any culture tested.
We also confirmed that the expression of pseudotype
virus with HIV-1 envelope was significantly inhibited in
the cells that were stimulated with ICOS or CD28mAbs immediately after PHA stimulation, (Fig. 7A),
whereas similar treatment did not affect cell proliferation
(Fig. 7B).
Fig. 7. Effects of ICOS or CD28 stimulation immediately after PHA
stimulation. CD4+ PBMC were stimulated with PHA for 30 min, washed,
and cultured on plates precoated with immobilized ICOS or CD28 mAbs or
control mouse IgG (1 Ag/ml) in the presence of IL-2. HIV-1 expression (A)
and proliferation (B) of these cells were examined. (A) Two days after
stimulation, the cells were infected with pseudotype virus with a HIV-1
envelope, and further cultured for 48 h in the mAb-coated wells, and then
luciferase activity was measured. *P < 0.05. (B) The proliferation of the
cells was measured by the [3H]thymidine incorporation method after a 3-
day culture without infection. The results show the mean F SD from
duplicate (A) or quadruplicate (B) determinations.
Fig. 8. The effects of Leflunomide on ICOS- or CD28-induced inhibition
of HIV-1 replication. (A) PHA-stimulated CD4+ PBMC infected with
HIV-1 NL4-3 were cultured in the absence (x) or presence of various
concentrations of Leflunomide (NF-nB-inhibitor) (n), PD98059 (MEK-
inhibitor) (E), or SB202190 (p38 MAP kinase inhibitor) ( ), for 4
days, and HIV-1 p24 levels in the supernatant were measured. (B)
PHA-stimulated CD4+ PBMC infected with HIV-1 NL4-3 were cultured
either without ( ) or with immobilized ICOS ( ) or CD28 ( ) mAbs
(5 Ag/ml) in 48-well flat-bottomed plates in either the absence or
presence of 20 AM Leflunomide, PD98059, or 10 AM of SB202190.
HIV-1 p24 levels in the supernatant were measured by ELISA 4 days
after infection. The results indicate the mean F SD from triplicate
determinations. Similar results were obtained in an independent experiment.
*P < 0.05.
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mediated by immobilized ICOS or CD28 mAbs
The intracellular transduction pathway underlying ICOS
signaling is not fully understood. Consequently, we inves-
tigated the effects of inhibitors for NF-nB (Leflunomide),
MEK (PD98059), and p38 MAP kinase (SB202190) on
ICOS- or CD28-induced inhibition of HIV-1 replication. As
shown in Fig. 8, Leflunomide significantly attenuated
CD28-induced inhibition of HIV-1 replication in CD4+ T
cells. Although Leflunomide alone suppressed HIV-1 rep-
lication, the coexistence of immobilized CD28 mAb
resulted in overwhelming viral replication. A low level of
enhancement in HIV-1 replication was also observed in
ICOS mAb-treated cells in the presence of Leflunomide,
although it was not statistically significant. In the presenceof PD98059, CD28 but not ICOS mAb significantly
enhanced HIV-1 replication. SB202190 marginally altered
the effects of ICOS- or CD28-mAbs. These results sug-
gested that CD28 and ICOS in a lesser degree mediated
positive signals in HIV replication besides inhibitory sig-
nals, and that the inhibitory signals were suppressed by
inhibiting NF-nB and/or MEK pathways.
Natural ligands for ICOS-inhibited HIV-1 replication
Finally, we assessed whether the natural ligands of ICOS
or CD28 affect HIV-1 replication. Recombinant chimeric
proteins of various B7-CD28 family molecules and the Fc
region of human IgG were added to CD4+ T cell cultures
Table 3
Effects of various soluble B7-CD28 family molecules on HIV-1 replication
Reagents HIV-1 p24 (pg/ml) in the supernatant of
HIV-1-infected CD4+ PBMC culture
Exp. 1 Exp. 2
Medium 77.2 F 13.8 168.8 F 20.6
Mouse IgG1 82.0 F 11.0 N.T.
CD28/Fc 65.3 F 9.1 139.8 F 4.1
CTLA-4/Fc 41.1 F 12.0* 84.9 F 17.0*
ICOS/Fc 72.5 F 8.0 N.T.
B7-1(CD80)/Fc 96.9 F 13.9 N.T.
B7-H2(B7h)/Fc 43.7 F 5.9* 95.9 F 13.4*
CD28/Fc +B7-H2/Fc N.T. 79.5 F 15.6*
CTLA-4/Fc +B7-H2/Fc N.T. 71.0 F 5.0*
PHA-stimulated CD4+ PBMC were infected with HIV-1 NL4-3, and
cultured in the medium containing IL-2 in the presence of 10 Ag/ml of the
indicated recombinant chimeric proteins of various B7-CD28 family
molecules and the human Fc region of IgG. HIV-1 p24 in the supernatant
was measured by ELISA after 4 days. The values indicate the mean F SD
from triplicate determinations.
N.T., not tested.
*P < 0.05.
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shown in Table 3. B7-H2 (B7h)/Fc and CTLA-4/Fc signif-
icantly suppressed HIV-1 replication. CD28/Fc produced
low levels of suppression, but the effects of ICOS/Fc were
minimal. B7-1 (CD80)/Fc enhanced viral replication. A
mixture of B7-H2 (B7h)/Fc and either CD28/Fc or CTLA-
4/Fc resulted in maximal suppression. These results indicate
that B7-H2 (B7h), a natural ligand of ICOS, suppressed
HIV-1 replication in a similar manner to ICOS-mAbs,
whereas B7-1, a natural ligand of CD28 and CTLA-4,
enhanced HIV-1 replication.Discussion
In the present study, we showed that ICOS transmitted
signals suppressing HIV-1 replication in CD4+ T cells in
vitro. ICOS-mAb suppressed HIV-1 replication when the
mAb was either added directly to the cell culture or was
immobilized. A soluble form of B7-H2 (B7h), a natural
ligand for ICOS, also suppressed HIV-1 replication. Immo-
bilized CD28-mAb suppressed HIV-1 replication in CD4+
cells as previously reported (Levine et al., 1996), while
direct application of CD28 mAb or its natural ligand B7-1
mostly enhanced viral replication consistently with other
reports, indicating that CD28 costimulation supports HIV-1
replication (Diegel et al., 1993).
Immobilized ICOS or CD28 mAbs significantly inhibited
replication of both X4 and R5 wild-type HIV-1 (Fig. 2). In
addition, these mAbs inhibited the expression of pseudotype
HIV-1 possessing HIV-1 envelope but not VSV-G envelope
(Fig. 5). Replication of pseudotype HIV-1 with VSV-G-
envelope was even enhanced especially when the cells were
pretreated with CD28 mAb. Moreover, immobilized ICOS
or CD28 mAbs significantly inhibited DNA synthesisduring the initial cycle of viral replication in the cells
infected with wild-type HIV-1 (Fig. 4). These observations
indicated that the entry stages of the viral life cycle were
mainly affected by these mAbs. However, CD4 and CXCR4
expression on the cell surface was not affected by stimula-
tion with ICOS and CD28 mAbs, and CCR5 levels were
even enhanced by treatment with these mAbs (Fig. 6). Thus,
the suppression of HIV-1 replication by these mAbs was not
attributable to the down-regulation of HIV-1 receptors or
coreceptors.
The cytokines and chemokines potentially modify HIV-1
replication. Stimulation of CD28 induces IL-2, while stim-
ulation of ICOS results in the production of other cytokines
(Beier et al., 2000; Coyle et al., 2000; Hutloff et al., 1999).
We measured several cytokines and chemokines in two
different culture conditions. When the cells were treated
with ICOS or CD28 mAbs immediately after PHA stimu-
lation, ICOS and CD28 stimulation enhanced IL-5 and IL-
10, but suppressed TNFa and IFNg production. When the
cells were treated with mAbs 4 days after PHA stimulation,
the levels of cytokine production were generally low, and
alteration of cytokine levels by ICOS and CD28 mAbs was
limited. Because HIV-1 expression was suppressed by these
mAbs in both culture conditions as well (Figs. 5B and 7A),
alteration of cytokines observed here was unlikely to be a
major reason for the viral suppression. The precise mecha-
nisms underlying the suppression of HIV-1 replication by
ICOS and CD28 mAbs remains to be determined.
The signaling pathways downstream of CD28 and ICOS
are not fully understood. Stimulation of the T cell receptor in
concert with CD28 induces activation of JNK, P38 MAPK,
AP-1, and interleukin-2 (Avraham et al., 1998; Faris et al.,
1996; Hehner et al., 2000), which involves activation of Vav
and Rac-1 (Raab et al., 2001; Salojin et al., 1999). Activa-
tion of NF-nB also occurs following CD28 costimulation,
which results from InB degradation (Harhaj and Sun, 1998;
Kane et al., 2002). Recent reports have shown that
MAPKKK might activate the IKK complex, and lead to
degradation of InB following CD28 costimulation (Tuosto
et al., 2000). In the present study, ICOS- and CD28-
mediated HIV-1 suppression was reversed by the NF-nB
inhibitor Leflunomide, which prevents degradation of InB
(Manna and Aggarwal, 1999). Because NF-nB also posi-
tively regulates HIV-1 replication itself, Leflunomide alone
suppressed HIV-1 production. Nevertheless, the levels of
HIV-1 replication in the presence of Leflunomide recovered
by stimulation with CD28 mAb to the control levels and
also with ICOS mAb to a lesser extent (Fig. 8). Leflunomide
has been shown to inhibit protein tyrosine kinase and MAP
kinase pathways involving MEK (Brazelton and Morris,
1996; Manna and Aggarwal, 1999). In the presence of
PD98059, the MEK inhibitor, CD28, but not ICOS mAb,
enhanced HIV-1 replication (Fig. 8). These results implies
that the CD28-mediated positive effects on HIV-1 replica-
tion overcame its inhibitory effects in the presence of
Leflunomide or PD98059, indicating that the CD28-medi-
X. Zhou et al. / Virology 325 (2004) 252–263260ated signals suppressing HIV-1 replication might involve the
NF-nB and MEK pathways. ICOS also showed a weak
positive effect on HIV-1 replication in the presence of
Leflunomide, indicating that its inhibitory effects might
involve partly common pathways to those of CD28.
Among the chimeric Fc-fusion proteins with various B7-
CD28 family molecules tested, CTLA-4/Fc and B7-H2
(B7h)/Fc significantly inhibited HIV-1 replication in
CD4+ PBMC (Table 2). CTLA-4/Fc, known to efficiently
block interactions between B7-1 (CD80)/B7-2 (CD86) and
CD28, suppressed replication of HIV-1. A similar suppres-
sion of HIV-1 replication by CTLA-4/Fc has been pre-
viously reported (Diegel et al., 1993; Smithgall et al.,
1995). This occurs probably because CTLA-4/Fc blocked
the positive regulation through B7-1 (CD80)/B7-2 (CD86)
that is expressed in a small proportion of PBMC. Although
immobilized CD28-mAb mediated HIV-1 suppression in
vitro, natural ligands of CD28 may preferentially mediate
positive signals for HIV-1 replication. This notion is partly
supported by previous reports showing that stimulation of
CD28 with cross-linking mAb, but not with natural ligand
B7-1, could activate ERK2 and p21ras (Nunes et al., 1994).
Because B7-H2 (B7h) is a natural ligand of ICOS, it was
not unexpected that B7-H2 (B7h)/Fc suppressed HIV-1, as
B7-H2 (B7h)/Fc binds ICOS and potentially activates sig-
nals downstream to ICOS on CD4+ T cells. This is consis-
tent with our current findings that ICOS mAbs mediated
suppression of HIV-1. The simple addition of ICOS/Fc,
which is capable of binding B7-H2 (B7h), to the PBMC
culture did not alter HIV-1 replication, suggesting that the
levels of natural ligands of ICOS present in the culture is
insufficient to suppress HIV-1. Nevertheless, suppression of
HIV-1 replication by B7-H2 (B7h)/Fc indicates that natural
or artificial ligands of ICOS potentially elicit suppressive
effects on HIV-1 replication.
B7-H2 (B7h) is more broadly expressed than B7-1
(CD80)/B7-2 (CD86) in both lymphoid and a variety of
nonlymphoid tissues (Swallow et al., 1999), implying that
ICOS-expressing cells could be regulated by various pe-
ripheral cells. A recent clinical study on HIV-1 infection
showed that ICOS expression peaked during the early
stages of primary infection, dropped to control levels in
the asymptomatic period, and subsequently increased as
AIDS developed (Lucia et al., 2000). They also showed
that HIV-1 gp120 induced transient ICOS expression in
naı¨ve T cells. Our results suggest that ICOS stimulation
may render uninfected T cells resistant to HIV-1 replica-
tion, and less efficiently suppress HIV-1 expression in
persistently infected cells. ICOS-mediated suppression of
HIV-1 replication may play some roles in regulating HIV-1
in vivo.
In conclusion, stimulation of ICOS by mAb or its
ligands mediated suppression of the early steps of HIV-1
replication in CD4+ PBMC. These findings contribute to
our understanding of HIV-1 regulation in vivo, and the
development of strategies to control HIV-1.Materials and methods
Cells
PBMC from healthy individuals were isolated by Ficoll-
Hypaque density centrifugation. CD4+ T cell fractions were
negatively purified from PBMC by magnetic cell sorting
following incubation with a cocktail of mAbs for CD8,
CD14, CD16, CD19, CD36, CD56, CD123, TCRgy, and
Glycophorin A, using MACS Cell Isolation Kits (Miltenyi
Biotec, Bergisch Gladbach, Germany). Flow cytometry
showed that these fractions contained 93% CD4+ cells.
Unfractionated PBMC or CD4+ T cells were stimulated
with 0.05% PHA P (Becton Dickinson, MD) for 30 min,
washed, and then cultured in RPMI 1640 (GIBCO BRL,
Long Island, NY) supplemented with 10% heat-inactivated
fetal calf serum (FCS), 10 U/ml recombinant human inter-
leukin-2 (IL-2) (Shionogi, Osaka, Japan) and 2 mM L-
glutamine, 100 U/ml penicillin, and 100 Ag/ml streptomycin
sulfate at 37 jC in a 5% CO2 incubator at a concentration of
1  106 cells/ml for 4–6 days. Cells were then used for
HIV-1 infection. In some experiments, Dynabeads (Dynal
A.S., Oslo, Norway) coated with anti-CD8 mAbs were used
to enrich CD4+ PBMC. 293T cells were maintained in
Dulbecco’s Modification of Eagle’s Medium (ICN Biomed-
icals Inc., OH) supplemented with 10% FCS.
Flow cytometric analysis
The cells were incubated with mAbs antigens or control
mouse immunoglobulin, washed, and subsequently stained
with FITC-conjugated goat anti-mouse IgG + IgM mAbs
(Immunotech, Marseilles, France) for 30 min at room
temperature. The cells were washed and analyzed using a
flow cytometer (FACS Calibur, Becton Dickinson, San Jose,
CA).
Antibodies and reagents
The mAbs to human CD28 family molecules used were
TN228, anti-CD28 (Lanier et al., 1995), MIH8, anti-CTLA-
4, SA12, anti-ICOS (Sakamoto et al., 2001), and MIH4,
anti-PD-1 (Youngnak et al., 2003), all of which were
prepared as purified mouse IgG1. MIH8 anti-CTLA4 was
generated by immunizing DBA/2 mice with human CTLA-
4-transfected P815 cells (Oki et al., 1999). SA12 was kindly
provided by Japan Tobacco Inc. (Osaka, Japan). Fluorescein
isothiocyanate (FITC)-conjugated CD4, phycoerythrin (PE)-
conjugated CXCR4 and CCR5, and their isotype-matched
control antibodies were purchased from BD Bioscience (San
Diego, CA). Human CD28/Fc, CTLA-4/Fc, B7-1/Fc, and
B7-H2/Fc, which were chimeric recombinant proteins fused
to the Fc region of human IgG, were purchased from R & D
Systems, Inc. (Minneapolis, MN). Human ICOS/Fc was
provided by Japan Tobacco Inc. A NF-kB inhibitor Leflu-
nomide, MEK (MAPKK) inhibitor PD98059 (Sigma-
X. Zhou et al. / Virology 325 (2004) 252–263 261Aldrich, St. Louis, MO), and p38 MAP kinase inhibitor
SB202190 (Calbiochem, San Diego, CA) were also used.
Proliferation assay
Cell proliferation was measured using the [3H]thymidine
uptake method. PHA-stimulated CD4+ T cells cultured for
4–6 days in a medium containing IL-2 were incubated in
96-well flat-bottom plates at a concentration of 105 cells/
200Al in either the presence or absence of mAbs for 4 days.
[3H]thymidine (37 kBq) was added into each well during the
last 16 h. Cells were then harvested on a glass filter, and the
incorporation of [3H]thymidine into the cells was monitored
with a MicroBeta scintillation counting system (Pharmacia
Biotech, Cambridge, UK).
Cytotoxicity test
PHA-stimulated CD4+ T cells cultured in IL-2-contain-
ing medium for 4–6 days were incubated in 96-well flat
bottom plates at a concentration of 105 cells/well in either
the presence or absence of mAbs, and LDH released into the
supernatant was monitored every 24 h over 3 days using a
Non-Radioactive Cytotoxicity Assay Kit (Promega, Madi-
son, WI).
Virus preparation and infection
X4 HIV 1 strain NL4-3 (Adachi et al., 1986) and R5
HIV-1 strain JR-CSF (Koyanagi et al., 1987), kindly
provided by Dr. Y. Koyanagi (Tohoku University), were
propagated in PBMC and the supernatant was used as virus
source. For HIV-1 infection, PHA-stimulated unfractionated
or CD4+ PBMC were cultured in a medium containing IL-
2 for 4–6 days, incubated with HIV-1-containing superna-
tant at a concentration of 4  106/ml for 2 h at 37 jC,
washed, and then cultured in a fresh medium containing IL-
2. HIV-1 pseudotype virus was prepared as described
elsewhere (Masuda et al., 1995; Planelles et al., 1995).
Briefly, using Lipofectamine (GIBCO BRL), 106 of 293T
cells were transfected with 1 Ag each of pNL4-3lucDenv
vector and pLET-LAI (Poon et al., 1998) or pHCMVG
(Yee et al., 1994), all of which were kindly provided by Dr.
Irvin S.Y. Chen, University of California. pNL4-3 lucDenv
is an envelope defective pNL4-3 vector containing the
luciferase gene inserted at the Nef site (Masuda et al.,
1995). pLET-LAI encodes envelope proteins of HIV-1 LAI
strain (Poon et al., 1998), and pHCMVG encodes a
vesicular stomatitis virus envelope (Yee et al., 1994).
Culture supernatant (5 ml) of the transfected 293T cells
was harvested 48 h posttransfection, filtered through a
0.45-Am filter, and used as pseudotype HIV-1. For infec-
tion, PHA-stimulated CD4+ T cells were incubated for 3
h with a pseudotype HIV-1-containing supernatant that had
been treated with DNase I (140 u/ml, Worthington, NJ) in
the presence of 10 mM MgCl2 at 37 jC for 1 h to avoidDNA contamination before infection. The cells were then
washed and cultured in a IL-2-containing medium at a
concentration of 5  105 cells/ml in 24- or 12-well plates
for 48 h in either the presence or absence of mAbs. Virus
replication was determined from luciferase activity.
Treatment of HIV-1-infected cells with mAbs
MAbs at concentrations ranging between 0.025 and
10 Ag/ml were either added directly to the culture or pre-
coated in the wells before culture. For precoating, mAbs
diluted in PBS was incubated overnight in 96-well or 48-well
flat-bottomed plates at 4 jC. The wells were washed with
PBS immediately before the culture of HIV-1-infected cells.
Analysis of HIV-1 cDNA synthesis
HIV-1-infected cells were harvested after various incu-
bation periods, washed, and 106 cells were disrupted in a
150 Al urea lysis buffer (4.7 M urea, 1.3% sodium dodecyl
sulfate, 0.23 M NaCl, 0.67 mM EDTA [pH 8.0], 6.7 mM
Tris–HCl [pH 8.0]) and underwent phenol–chloroform
extraction and ethanol precipitation. Precipitated DNA
was then resuspended in 30 Al water. A 0.5 Ag DNA
pellet of each sample underwent PCR using primer pairs
(Zack et al., 1990) amplifying a DNA fragment between
HIV-1 LTR U3 and HIV gag (M667/M661) for 35 cycles
at 95 jC for 1 min, 65 jC for 2 min, and 72 jC for 2 min
as previously described (Tsurutani et al., 2000; Zack et al.,
1990). For HIV-1 DNA standards, 250–5000 copies of
linearized HIV-1 JR-CSF DNA were amplified in parallel.
Amplified products were resolved on a 2% agarose gel and
stained with SYBER-Green (FMC Bioproduct, Rocklan,
MN).
Enzyme-linked immunosorbent assay (ELISA)
HIV-1 p24, human RANTES, IFN-g, SDF-1a, and MIP-
1a in cell-free supernatants were measured by HIV-1 p24
Antigen ELISA kit (ZeptoMetrix, NY), and human
RANTES, IFN-g, SDF-1a, and MIP-1a immunoassay kit
(R & D Systems), respectively. Absorbances were measured
at 450 nm using microplate reader (Bio-Rad, Hercules, CA)
and analyzed with Microplate Manager III software.
Measurement of cytokines
Human IL-4, IL-5, IL-10, and TNFa in the culture
supernatants were measured by the Cytometric Bead Array
Kit (BD Biosciences, Pharmingen, CA) in accordance with
the manufacturer’s instructions.
Luciferase assay
For luciferase analysis, cells were lysed by 100 Al of 1
luciferase lysis buffer (Promega) 24 h postinfection, and
X. Zhou et al. / Virology 325 (2004) 252–263262luciferase expression was measured with a luciferase assay
system (Lumat, EG&G Berthold, Germany).
Statistical analysis
Differences among HIV-1 p24 values of individual
sample groups vs. controls were evaluated by Dunnett’s t
test using SPSS Base 11.0J (SPSS Inc., Chicago, IL). P
values less than 0.05 were considered to be statistically
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